Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost

Alayed, Yasir; Loblaw, Andrew; McGuffin, Merrylee; Chung, Hans T.; Tseng, Chia‐Lin; D’Alimonte, Laura; Cheung, Patrick; Liu, Stanley K.; Chu, William; Szumacher, Ewa; Helou, Joelle; Ravi, Ananth; Haider, Masoom A.; Mamedov, Alexandre; Zhang, Liying; Morton, Gerard

doi:10.1016/j.radonc.2020.09.007

Cited by 22 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As already reported in other series, in the SiFEPI trial local relapse occurred in or close to the initial anatomical site [12,13,15,17]. However, no significant difference in terms of dosimetric data were observed between patients with and without local relapse (e- [12,14,15].…”

Section: Discussionsupporting

confidence: 53%

Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial

Hannoun‐Lévi

Chand-Fouché

Pace-Loscos

et al. 2022

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 53%

Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial

Hannoun‐Lévi

Chand-Fouché

Pace-Loscos

et al. 2022

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

“…6 By making plans more robust to source positioning errors, both sensitivity and specificity of in-vivo source tracking devices in detecting clinically relevant source positioning errors may be improved. 6 An approach, such as this, may be even more valuable in the context of HDR prostate BT plans treating the entire prostate plus a boost to the dominant intraprostatic lesion(s), 19 and even more so in the context of focal treatments to these lesions within the prostate. 20 The effect of prostate motion relative to planned positions in stereotactic ablative body radiotherapy (SABR) has also been studied.…”

Section: Discussionmentioning

confidence: 99%

HDR prostate brachytherapy plan robustness and its effect on in‐vivo source tracking error thresholds: A multi‐institutional study

et al. 2022

View full text Add to dashboard Cite

The purpose of this study was to examine the effect of departmental planning techniques on appropriate in-vivo source tracking error thresholds for high dose rate (HDR) prostate brachytherapy (BT) treatments, and to determine if a single in-vivo source tracking error threshold would be appropriate for the same patient anatomy. Methods: The prostate, rectum, and urethra were contoured on a single patient transrectal ultrasound (TRUS) dataset. Anonymized DICOM files were disseminated to 16 departments who created an HDR prostate BT treatment plan on the dataset with a prescription dose of 15 Gy in a single fraction. Departments were asked to follow their own local treatment planning guidelines. Source positioning errors were then simulated in the 16 treatment plans and the effect on dose-volume histogram (DVH) indices calculated. Change in DVH indices were used to determine appropriate in-vivo source tracking error thresholds. Plans were considered to require intervention if the following DVH conditions occurred: prostate V100% < 90%, urethra D0.1cc > 118%, and rectum tt Dmax > 80%. Results: There was wide variation in appropriate in-vivo source tracking error thresholds among the 16 participating departments, ranging from 1 to 6 mm. Appropriate in-vivo source tracking error thresholds were also found to depend on the direction of the source positioning error and the endpoint. A robustness parameter was derived, and found to correlate with the sensitivity of plans to source positioning errors. Conclusions: A single HDR prostate BT in-vivo source tracking error threshold cannot be applied across multiple departments, even for the same patient anatomy. The burden on in-vivo source tracking devices may be eased through improving HDR prostate BT plan robustness during the plan optimisation phase.

show abstract

“…Single-fraction escalation to 20.5 Gy as monotherapy produced a 6-year biochemical control rate of 82% in a cohort of low-and intermediate-risk patients, which is only marginally better than those previously reported with 19 Gy [67]. Alayed et al compared single 19 Gy HDRBT with or without an additional MRI-guided focal dominant intraprostatic lesion (DIL) boost to at least 23 Gy in low-or intermediate-risk disease patients in a phase II clinical trial [68]. The median dose to the dominant lesion was 27.2 Gy.…”

Section: Hdrbt Fractionationmentioning

confidence: 93%

Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy

Martin

Lilleby

et al. 2020

Cancers

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common noncutaneous solid organ malignancy among men worldwide. Radiation therapy is a standard of care treatment option that has historically been delivered in the form of small daily doses of radiation over the span of multiple weeks. PCa appears to have a unique sensitivity to higher doses of radiation per fraction, rendering it susceptible to abbreviated forms of treatment. Stereotactic body radiation therapy (SBRT) and high-dose-rate brachytherapy (HDRBT) are both modern radiation modalities that allow the precise delivery of ablative doses of radiation to the prostate while maximally sparing sensitive surrounding normal structures. In this review, we highlight the evidence regarding the radiobiology, oncological outcomes, toxicity and dose/fractionation schemes of SBRT and HDRBT monotherapy in men with low-and intermediate-risk PCa.

show abstract

Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost

Cited by 22 publications

References 20 publications

Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial

Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial

HDR prostate brachytherapy plan robustness and its effect on in‐vivo source tracking error thresholds: A multi‐institutional study

Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy

Contact Info

Product

Resources

About